Axsome Therapeutics gets $225 million term loan via Hercules

By Devika Patel

Knoxville, Tenn., Sept. 29 – Axsome Therapeutics, Inc. has secured a $225 million term loan facility with Hercules Capital, Inc., according to a press release.

The “committed capital strengthens the company’s balance sheet through the anticipated commercial launches of its two lead product candidates, AXS-05 for major depressive disorder and AXS-07 for migraine, and extends its cash runway into at least 2024, based on current operating plans,” the company stated in a press release.

The biopharmaceutical company is based in New York.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.